Pop culture makes cloning look as simple as tapping into amber-trapped mosquitoes or an overnight transformation through injection. The reality inside the lab is messier, far more expensive, and humbled by the intricacies of reproduction that we still do not understand well. On Friday at 10AM, the Science Track hosted “30 Years of Real-Life Cloning: Where Are We Now?” in Hilton 209–211. Moderator Vaughan James led a discussion with biotech experts Topher Hunter, a veteran in medical device biologics; Dr. Jennifer Hardee, a Yale PhD specializing in engineered T-cells; and Dr. Eric Hall, a Stanford PhD bridging digital biology and translating to clinical uses.
The panel began by looking back three decades to Dolly the sheep, named for the late Dolly Parton. Dolly made global headlines as the first mammal successfully cloned. The panelists emphasized the sheer odds involved. It took more than 200 attempts before one worked. Dr. Hardee read the paper and determined that the scientists in the lab got lucky. Even modern attempts still often resemble “shotgunning the process and hoping one egg works.”
A major barrier between sci-fi imagination and real science is epigenetics. Dr. Hall explained DNA expression through methylation, likening it to “the road cones of the genetic highway.” In reproductive cloning, scientists take the cell, remove the nucleus, and replace it with the nucleus of the animal they are trying to clone. The epigenetic signature is wiped and reestablished multiple times, introducing subtle variations that researchers still cannot fully dictate. Environmental impacts over time also impact DNA and we don’t understand that well. To truly clone, we need control over the entire process from beginning to end, and there’s still so much we just don’t understand about the human body.
Hunter also highlighted structural hurdles in primates: two crucial motor proteins required to pull chromosomes apart during cell division are closely bound to the nucleus, and those get ripped apart when the nucleus is replaced, which is one reason why human reproductive cloning has never succeeded.
The speakers made a clear distinction between reproductive cloning (making full organisms) and therapeutic cloning (replicating cells or tissues). While commercial pet cloning exists for wealthy owners, the offspring may not even share the exact appearance or coat pattern of the donor due to X-chromosome inactivation and mitochondrial DNA differences. Dr. Hall pointed out that high costs will keep whole-organism cloning a “rich person’s game.”
From an ethical standpoint, the panelists agreed that preserving endangered species shows positive promise for cloning, while noting that cloning does not fix the underlying environmental damage (i.e. human encroachment on habitat, poisoning pests) that is driving the endangered species to extinction in the first place. Meanwhile, de-extinction efforts face enormous logistical hurdles. They noted Jurassic Park will not happen because the short half-life of ancient DNA doesn’t last this long. But even if you did de-extinct a species, how do you reintroduce them to the world without messing up existing biomes?
When asked why regenerative medicine hasn’t become more viable, the panel cited the staggering complexity of organs alongside the limits of time and cost. Organs like the liver are intricate, non-monolithic structures that cannot simply be 3D printed overnight. Patients requiring heart bypasses rarely have months to wait for lab-grown replacements.
Still, the panelists agreed that even unsuccessful trials push medicine forward. “We are constantly learning about another layer of control lasagna that we didn’t recognize,” Dr. Hardee said, describing scientific progress as “well that didn’t work the way I thought it would, I wonder why?” Progress becomes “two steps forward and one step sideways.”
Dr. Hall echoed the sentiment, encouraging researchers to mine data from apparent failures. In his frustration during one particular project, he poured water on some cells, thinking that would kill them. Instead, cool things happened that lead to three papers for him.
When someone asked about the use of AI involvement in the industry, Dr. Hall noted “we’re not there yet with AI.” AI is primarily good at sophisticated pattern matching, but then you have a human verify if the pattern means anything. Also, AI doesn’t understand the changes in our scientific thinking over time.
As for the true viability of primate cloning and fully engineered complex organs, those may remain decades or centuries away, but Dr. Hardee noted each little step helps “chip away at the problem.”
